Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod

The safety profile of fingolimod 0.5 mg, approved therapy for relapsing multiple sclerosis, is well established in clinical and real‐world studies. As fingolimod is teratogenic in rats, it was considered important to assess the concentrations of fingolimod and its active metabolite, fingolimod‐phosp...

Descripción completa

Detalles Bibliográficos
Autores principales: David, Olivier J., Berwick, Amy, Pezous, Nicole, Lang, Michael, Tiel‐Wilck, Klaus, Ziemssen, Tjalf, Li, Peng, Hara, Hisanori, Schmouder, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814852/
https://www.ncbi.nlm.nih.gov/pubmed/29266794
http://dx.doi.org/10.1002/cpdd.424

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814852/
https://www.ncbi.nlm.nih.gov/pubmed/29266794
http://dx.doi.org/10.1002/cpdd.424

Ejemplares similares